Vertex Pharmaceuticals Incorporated (VRTX) Q1 2018 Earnings Results

Vertex Pharmaceuticals Beats on EPS, Stock Up 2.36%

Vertex Pharmaceuticals reported a strong EPS performance, exceeding expectations by over 24%. The stock reacted positively, rising 2.36% following the announcement. Investors may view the solid EPS as a sign of the company's financial health, even without revenue figures to assess.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.76	N/A	+24.54%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding the company's performance. They emphasized the importance of innovation in driving future success.

Management expressed satisfaction with the EPS performance despite not providing revenue figures.

The team highlighted ongoing efforts in research and development as key to future growth.

Vertex Pharmaceuticals Beats on EPS, Stock Up 2.36%

Key numbers

Management commentary

Vertex Pharmaceuticals Incorporated

More earnings this week

Vertex Pharmaceuticals Beats on EPS, Stock Up 2.36%

Key numbers

Management commentary